Interpretation of the World Health Organization’s Global Tuberculosis Report 2025

doi:10.19983/j.issn.2096-8493.20250178

Abstract

Abstract:

On November 12, 2025, the World Health Organization published the Global Tuberculosis Report 2025, which presents a comprehensive and up-to-date assessment of the global tuberculosis epidemic and the progress of response efforts at global, regional, and national levels in alignment with established international commitments, strategies, and targets. By analyzing the report, this paper aims to assist tuberculosis control practitioners in gaining a thorough understanding of the global burden of tuberculosis, advancements in patient-centered diagnosis, treatment, and care, as well as key strategic directions for accelerating progress toward ending the tuberculosis epidemic.

Key words: Tuberculosis, World Health Organization, Consensus development conference

CLC Number:

R521

Qu Yan, Li Tao, Ma Wenbin, Xu Caihong, Yan Tianxin, Huang Fei, Zhao Yanlin, Zhang Hui. Interpretation of the World Health Organization’s Global Tuberculosis Report 2025[J]. Journal of Tuberculosis and Lung Disease , 2025, 6(6): 613-623. doi: 10.19983/j.issn.2096-8493.20250178

Figures/Tables 12

References 9

[1]	World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization, 2025.
[2]	World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
[3]	World Health Organization. The End TB Strategy. Geneva: World Health Organization, 2015.
[4]	World Health Organization. Guidance on evidence generation on new regimens for tuberculosis treatment. Geneva: World Health Organization, 2024.
[5]	World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention-tuberculosis preventive treatment, second edition.Geneva: World Health Organization, 2024.
[6]	World Health Organization. Global Strategy for Tuberculosis Research and Innovation (WHA73.3). Seventy-third World Health Assembly. Geneva:World Health Assembly, 2020.
[7]	World Health Organization. National surveys of costs faced by TB patients and their households, 2015—2021. Geneva: World Health Organization,2023.
[8]	World Health Organization. Adaptation and implementation of WHO’s Multisectoral accountability framework to end TB (MAF-TB): best practices.Geneva: World Health Organization, 2022.
[9]	中华人民共和国国家疾病预防控制局. 全国结核病防治规划(2024—2030年). 国疾控传防发〔2024〕19号. 2024-12-05 [2025-11-19].

指标	结核病发病率下降百分比 (%)(与2015年基线相比)	结核病死亡绝对人数减少百分比 (%)(与2015年基线相比)	因结核病而面临灾难性支出的受影响家庭百分比(%)(2015年水平未知)
2024年进展	12	29	47
里程碑目标	50	75	0

指标	进展	全球阶段性目标
被诊断为结核病的患者,最初接受了世界卫生组织推荐的快速检测	2024年为54%	到2027年实现100%
结核病诊断与治疗覆盖率	2024年为78%	到2027年达到90%
健康与社会福利的覆盖范围	2024年为44%	到2027年实现100%
HIV感染者结核病预防性治疗覆盖率	2024年为58%	到2027年达到90%
家庭密切接触者结核病预防性治疗覆盖率	2024年为25%	到2027年达到90%
实现结核病预防、诊断、治疗和关怀普及的资金	2024年为59亿美元	到2027年每年220亿美元
结核病研究资金	2023年为12亿美元	到2027年每年50亿美元
到2027年,将有90%安全且有效的结核病新疫苗问世	截至2025年8月,有6项处于 Ⅲ期临床试验的疫苗	启动推广计划, 最好在5年内完成

[1]	Ding Feng, Lu Shuihua. Interpretation of the fouth edition of WHO consolidated guidelines on tuberculosis, Module 3:diagnosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 624-633.
[2]	National Clinical Research Center for Infectious Disease/Shenzhen Third People’s Hospital, Tuberculosis and Diabetes Branch of Chinese Antituberculosis Association, Multidisciplinary Diagnosis and Treatment Branch of Chinese Antituberculosis Association. Expert consensus on the rational use of rifamycins in the treatment of tuberculosis with comorbidities [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 634-658.
[3]	Ke Ran, Zheng Rongrong, Zheng Chunmei, Xue Jianhang, Liu Xunrui, Lin Weiqi, Li Lu, Cao Hong. Analysis of spatiotemporal distribution dynamics of pulmonary tuberculosis and correlation with precipitation in Xiamen, China (2014—2023) [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 696-702.
[4]	Tian Xiaomei, He Xiaoxue, Lei Juan, Wang Xiaowei, Gu Jianjun. Analysis of treatment outcomes and influencing factors for bacteriologically positive pulmonary tuberculosis in Ningxia Hui Autonomous Region from 2019 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 703-709.
[5]	Sha Xiaolan, Tian Xiaofu, Tian Xiaomei, Liu Tao, Lei Juan. Analysis of treatment outcome and its influencing factors of multidrug/rifampicin-resistant pulmonary tuberculosis patients in Ningxia Hui Autonomous Region from 2018 to 2022 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 710-716.
[6]	Meng Xuejia, Tang Liusheng, Dong Jie, Zeng Qingxue. Analysis of drug resistance characteristics of newly diagnosed pulmonary tuberculosis patients in Liuzhou City, Guangxi Zhuang Autonomous Region [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 717-724.
[7]	Liao Wenping, Zhang Liyi, Zhang Wen, Su Qian. Analysis of treatment outcomes and influencing factors among student pulmonary tuberculosis patients in Chongqing from 2020 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 725-730.
[8]	Su Wei, Liu Yinshan, Luo Xushan, Gulizibaier·Saimaier , Turhong·Wushouer , Paerhati·Shalayiding , Qi Haibo, Yasen·Tuerxun , Gulmira·Imin , Maiwelanjiang·Abulimiti , Zhou Linjun, Huang Fei. Observation on the efficacy of all-oral standardized short-course treatment for 80 cases of multidrug/rifampicin-resistant pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 731-737.
[9]	Guan Tingting, Wang Ying, Wang Lianzhi. The diagnostic value of thoracoscopic cryobiopsy in internal medicine for suspected tuberculous pleurisy [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 738-746.
[10]	Liu Quanxian, Zhao Zhaoliang, Zong Zhaojing, Chen Ling, Lan Yuanbo. Deletion of the pks5 gene (Rv1527c) impairs intracellular survival in macrophages and modulates inflammatory cytokine expression in Mycobacterium tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 747-752.
[11]	Chinese Association of Integrative Medicine China Association of Chinese Medicine Chinese Medical Association. Diagnosis and treatment of the integrated Chinese and western medicine guidelines for drug-resistant pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(5): 477-494.
[12]	Multidisciplinary Diagnosis and Treatment Branch of Chinese Antituberculosis Association , National Clinical Research Center for Infectious Disease/Shenzhen Third People’s Hospital, Beijing Chao-Yang Hospital , Capital Medical University , Guangdong Lung Cancer Institute . Expert consensus on the diagnosis and treatment of coexistent pulmonary tuberculosis and lung cancer [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(5): 495-515.
[13]	Wei Daijue, Tong Chongxiang. The diagnostic value of adenosine deaminase in pleural fluid, whole blood γ-interferon, and interleukin-2 for tuberculous pleurisy [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(5): 525-531.
[14]	Chen Fang, Zhao Yajun, Wang Rui, Feng Yanguo, Zhang Dezhi. A case of central nervous system tuberculosis with pituitary involvement and diabetes insipidus: A literature review [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(5): 532-537.
[15]	Zhang Ying, Ye Yun, Zuo Xiuying, Ding Jiaqi, Wang Fang. Summary of the best evidence for nutritional management in patients with both pulmonary tuberculosis and diabetes [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(5): 538-543.